实验性铬酸钠中毒大鼠肝Ⅳ型胶原变化的研究

用抗Ⅳ型胶原单克隆抗体免疫组化法、病理组织学及图象分析对实验性铬酸钠中毒大鼠肝进行了研究。一次气管内注入0.04 mg/kg Na_2CrO_42天后肝组织即出现病理改变和Ⅳ型胶原免疫组化阳性产物增加。一次注入0.98 mg/kg Na_2CrO_4后第2～28天Ⅳ型胶原免疫组化阳性产物均较对照组增加。增加的程度与肝病变程度一致,且随着肝组织的修复而下降。结果说明铬染毒所致的Ⅳ型胶原的改变与肝的病理改变密切相关。     

毒死蜱对家白蚁毒杀作用的时间与剂量效应

用含不同毒死蜱浓度的毒土对家白蚁（Ｃｏｐｔｏｔｅｒｎｅｓ ｆｏｕｍｏｓａｍｕｓ Ｓｈｉｒａｋｉ）进行了生物测定,浓度范围为０．０１５－０．４８ｍｇ／ｋｇ。观察２周。实验观察发现土壤中毒死蜱浓度为０．４８－０．０６ｍｇ／ｋｇ时,白蚁接触毒土出现的死亡高峰为４小时至２天;在０．０３ｍｇ／ｋｇ时,死亡高峰在１周以后;而浓度为０．０１５ｍｇ／ｋｇ时,２周内仍观察不到白蚁死亡。所获的生物测定数据很好地拟合时     

肾上腺素受体拮抗剂对大鼠急性肝损害影响的研究

雄性ＳＤ大鼠３３只,体重１８０—２５０ｇ,随机分成四组。正常对照组６只;哌唑嗪组８只,于实验第１、２、３日上午用哌唑嗪灌胃（１ｍｇ／ｋｇ体重）共３次,第２日下午腹腔注射半乳糖胺（６００ｍｇ／ｋｇ体重）１次,第４日上午处死动物,取肝脏及血清作有关检查;普萘洛尔组及Ｎ．Ｓ对照组分别用普萘洛尔（２ｍｇ／ｋｇ体重）及Ｎ．Ｓ（１０ｍｌ／ｋｇ体重）代替哌唑嗪灌胃,处理程序同哌唑嗪组。结果表明：一、哌唑嗪能显著减轻肝脏病变及血清ＡＬＴ的升高。二、哌唑嗪对肝损害后肝组织ＳＤＨ、Ｍｇ２＋－ＡＴ－Ｐａｓｅ、ＣｈＥ、ＡＣＰ、ＣＣｏ等酶活性的恢复有显著效果。三、哌唑嗪组ＬＰＯ明显低于Ｎ．Ｓ对照组（Ｐ＜０．０１）而ＳＯＤ活性明显高于Ｎ．Ｓ对照组（Ｐ＜０．０１）。普萘洛尔组各项指标同对照组比较均无显著差异（Ｐ＞０．０５）。提示：哌唑嗪对大鼠实验性肝损害有一定的保护作用。     

MS-551抗缺血性室性心律失常的实验研究

目的：研究新型Ⅲ类抗心律失常药物ＭＳ－５５１,即１,３二甲基－６「２－（Ｎ－２羟乙基－３－４硝苯丙氨基）乙氨基」－２,４（１Ｈ,３Ｈ）－盐酸嘧啶二酮（ＭＳ）,对麻醉犬心肌的电作用和对缺血性室性心律失常的防治效果。方法：测定用药（ＭＳ首剂０．５ｍｇ／ｋｇ于５ｍｉｎ内静推,维持量０．５ｍｇ／ｋｇ静滴３０ｍｉｎ）前后下沉犬心肌房室不应期,并观察ＭＳ「首剂０．３ｍｇ／ｋｇ于５ｍｉｎ内静推,维持量０．５ｍｇ     

公雏鸡糖皮质激素受体与免疫功能的相关性

研究了用于不同剂量（７５、５０、２５、１０ｍｇ／ｋｇ）ＲＵ４８６阻断公雏鸡糖皮质激素受体１天或连续３天免疫指标变化情况。ＲＵ４８６７５和５０ｍｇ／ｋｇ阻断ＧＲ２４ｈ,公雏鸡脾淋巴细胞ＩＬ－２、ＩＦＮ诱生活性和Ｔ、Ｂ淋巴细胞增殖活性降低（Ｐ〈０．０１）,外周血淋巴细胞、单核细胞、ＡＮＡＥ＋细胞减少（Ｐ〈０．０１）;胸腺、脾脏、法氏囊的体重比减小（Ｐ〈０．０１）。每日ＲＵ４８６５０ｍｇ／ｋｇ连续３天阻     

硒拮抗氟对肾脏损害的酶组织化学观察

本实验以酶组织化学方法（ＳＤＨ、ＬＤＨ、ＡＣＰ、ＡＬＰ）探讨硒对氟引起肾脏损害的拮抗作用。大鼠分为六组,Ａ组常规饮水;Ｂ组饮水含亚硒酸钠２ｍｇ／Ｌ;Ｃ组饮水中含氟化钠１５０ｍｇ／Ｌ;Ｄ、Ｅ、Ｆ组饮水中分别含氟化钠１５０ｍｇ／Ｌ,依次含亚硒酸钠０．５ｍｇ／Ｌ、２ｍｇ／Ｌ、４ｍｇ／Ｌ。８周后断头处死,观察肾脏组织中ＳＤＨ、ＬＤＨ、ＡＣＰ、ＡＬＰ的活性。结果表明,与Ａ组相比,Ｃ组近曲小管ＳＤＨ、ＡＬＰ活性减弱,ＬＤＨ、ＡＣＰ活性明显增加;Ｂ组ＳＤＨ、ＡＣＰ活性正常,基底膜清晰;Ｄ、Ｅ、Ｆ组均能提高ＳＤＨ活性,其中Ｅ组较稳定;Ｆ组ＡＣＰ活性较高。结果说明了氟引起肾近曲小管溶酶体的破坏,而硒（２ｍｇ／Ｌ）能稳定溶酶体膜,拮抗氟对肾脏的损害作用     

反复摄取烟碱对脑肌醇含量的影响

急性实验中,间隔５ｍｉｎ反复注射烟碱０．５,１．０,１．０,２．０,２．０ｍｇ／ｋｇｉｐ,３０ｍｉｎ后大鼠大脑皮层及海马中肌醇含量升高,但纹状体中肌醇含量无显著变化;相同条件下,氯化锂１０ｍｍｏｌ／ｋｇｉｐ３０ｍｉｎ后大脑皮层和海马中肌醇含量显著降低;慢性实验中,烟碱２．０－１０．０ｍｇ／ｋｇｓｃｂｉｄ１４ｄ后,大鼠大脑皮层中肌醇含量显著增高;烟碱２．６９－１１．５３ｍｇ／ｋｇ／ｄｐｏ６４ｄ后,大鼠大脑皮层中肌醇含量也显著增高。表明烟碱的作用不同于氯化锂,反复给予烟碱可使大鼠大脑皮层中肌醇含量增加。     

HBIG,无环鸟苷,干扰素联合对慢性乙型肝炎抗病毒效应观察

本文报道血清ＨＢＶ复制标志阳性的慢乙肝５４例,随机分为治疗组及对照组各２７例进行ＨＢＩＧ、无环鸟苷、干扰素联合近、远期抗病毒效应观察。治疗组为无环鸟苷第一周按２５～２０ｍｇ／ｋｇ／ｄ计后改１７～１５ｍｇ／ｋｇ／ｄ×５３天,共６０天;人白细胞干扰素１×１０６Ｕ肌注每周３次×４周,后改１．０×１０６Ｕ肌注每周２次×６周,共１０周;ＨＢＩＧ４００Ｕ肌注隔日１次,共１０周,对照组仅给予一般“保肝”药物。其中治疗组１８例,对照组１９例进行治后半年到２年追踪观察,结果近、远期ＨＢｃＡｇ、ＤＮＡＰ、ＨＢＶ－ＤＮＡ阴转率治疗组均高于对照组,其中治疗组近、远期ＨＢｃＡｇ,ＨＢＶ－ＤＮＡ阴转率均达４０％以上,明显高于对照组（Ｐ＜０．０５～０．０１）,治疗组近、远期各有４例及２例ＨＢｓＡｇ阴转,而对照组则无一例阴转,从近、远期综合抗病毒效应观察,治疗组全阴率分别为３３．３％、４４．４％,而对照组分别为３．７９％及０％,Ｐ＜０．０１,治疗组无明显毒副反应。对比单用无环鸟苷,全阴率３１．８％;无环鸟苷加干扰素两药联合全阴率３７．５％,均有所提高,达到４４．４％,值得进一步研究。     

蛇毒心脏毒素对荷瘤小鼠的抗肿瘤作用初步研究

目的探讨蛇毒心脏毒素（ＣＴＸ）对荷瘤小鼠Ｓ１８０腹水瘤细胞生长抑制的影响。方法小鼠腹腔接种Ｓ１８０活瘤细胞,连续１０ｄ分别腹腔注射ＣＴＸ０．８ｍｇ／ｋｇ、０．４ｍｇ／ｋｇ、０．２ｍｇ／ｋｇ,分析统计荷瘤小鼠的体重变化和癌细胞死亡率,并用有丝分裂完全阻断法分析体内癌细胞的有丝分裂过程。结果ＣＴＸ各剂量组荷瘤小鼠的体重抑制和癌细胞死亡率均有明显的剂量反应关系,与对照组相比有显著的差异（Ｐ＜０．０１）;镜检发现ＣＴＸ能抑制体内癌细胞的有丝分裂,表现在０．４ｍｇ／ｋｇ和０．８ｍｇ／ｋｇ实验组腹水Ｓ１８０细胞处于有丝分裂前期和中期的细胞数量明显减少,其ＭＩ值分别为０．７１％和０．８０％,比对照组显著减少（Ｐ＜０．００１）。结论ＣＴＸ对Ｓ１８０小鼠体内癌细胞的生长有抑制和杀伤作用,并通过干扰和阻断癌细胞的有丝分裂过程,抑制腹水的生长。     

电刺激膈神经中枢端对家兔动脉血压和血浆血管紧张素Ⅱ及肾神经传出放电的影响

电刺激家兔膈神经中枢端（ＳＣＰＮ）可引起动脉血压下降,此降压反应不能被剪断双侧颈迷走神经或静脉注射阿托品１ｍｇ／ｋｇ所阻断;但可以被静脉注射酚妥拉明２．０ｍｇ／ｋｇ或静脉注射心得安１．５ｍｇ／ｋｇ部分阻断。去除缓冲神经后,其降压反应更明显。降压反应后ｌｍｉｎ血浆血管紧张素Ⅱ水平降低（Ｐ＜０．０５）,肾神经传出放电（ＲＮＤ）减少（Ｐ＜０．０１）,上述结果表明,膈神经的感觉纤维参与血压调节。     

Biochemical and morphological evaluation of the effects of propolis on cisplatin induced kidney damage in rats

Cisplatin (CP) is a chemotherapeutic agent used to treat various types of cancer; nephrotoxicity is the most common adverse effect of the drug. We investigated the protective effects of propolis against CP induced kidney injury. Thirty-six male rats were divided into six equal groups: untreated control group, 50 mg/kg/day propolis group, 100 mg/kg/day propolis group, single-dose 7 mg/kg CP group, 7 mg/kg CP + 50 mg/kg/day propolis and 7 mg/kg CP + 100 mg/kg propolis. Rats were sacrificed after 14 days and kidneys were removed for histopathological and biochemical analyses. We used hematoxylin & eosin and periodic acid-Schiff staining to evaluate kidney histopathology and we used the TUNEL technique to assess apoptosis. We also measured total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), ischemia-modified albumin (IMA) and malondialdehyde (MDA) levels in tissue and blood specimens. Normal morphology was observed in the control, 50 mg/kg/day propolis and 100 mg/kg/day propolis groups by light microscopy. Degeneration of tubule cells, edema and tubule dilation were increased in the CP group compared to the control group. Degeneration of tubule cells and dilation of Bowman’s spaces were decreased in the CP + 50 mg/kg/day propolis and CP + 100 mg/kg/day propolis groups compared to the CP group. Tubule dilation decreased significantly in the CP + 100 mg/kg propolis group compared to the CP group. Also, the 7 mg/kg CP group exhibited altered proximal tubule epithelial cells, loss of brush border and thickening of the parietal layer of Bowman’s capsule in glomeruli and basal laminae of tubules. A normal brush border was observed in the CP + 50 mg/kg/day propolis and CP + 100 mg/kg/day groups. Serum OSI and MDA levels were increased in the CP group compared to the control group. Serum MDA levels decreased significantly in the CP + 50 mg/kg/day propolis and 100 mg/kg CP + propolis groups compared to the CP group. CP caused significant damage to kidney tissue; propolis exhibited dose-dependent prevention of tissue damage.     

Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat

Vancomycin, a glycopeptide antibiotic, has a broad spectrum against methicillin-resistant Staphylococcus aureus (MRSA). Because vancomycin induces renal dysfunction, the dose and the duration of its administration are limited. The mechanism of vancomycin-induced renal dysfunction is not known. We recently synthesized a hexamethylenediamine-conjugated cationic superoxide dismutase (AH-SOD) which rapidly accumulates in renal proximal tubule cells and inhibits oxidative injury of the kidney. The present work reports the protective effects of AH-SOD against vancomycin-induced renal dysfunction. Male Wistar rats (200-210 g) were intraperitoneally administered with either 200 or 400 mg/kg of vancomycin twice a day for 7 days. Either 5 mg/kg/day AH-SOD or saline was subcutaneously injected 5 min before every vancomycin injection. Biochemical analysis revealed that plasma levels of blood urea nitrogen and creatinine increased significantly in vancomycin-treated group by an AH-SOD-inhibitable mechanism. Histological examination revealed that vancomycin also elicited a marked destruction of glomeruli and necrosis of proximal tubule by an AH-SOD inhibitable mechanism. These results suggest that oxidative stress underlies the pathogenesis of vancomycin-induced nephrotoxicity and that targeting SOD and/or related antioxidants to renal proximal tubule cells might permit the administration of higher doses of vancomycin sufficient for eradication of MRSA without causing renal injury.     

帕妥珠单抗生物类似药SMMU-27 静脉注射对食蟹猴的重复给药毒性探索研究

目的:观察帕妥珠单抗生物类似药SMMU-27四周静脉注射对食蟹猴的安全性。方法:20只健康食蟹猴按体重随机分为阳性对照组、SMMU-27低、中、高剂量组和辅料对照组,每组4只,雌雄各半。低、中、高剂量组剂量分别为15、150和450 mg/kg,阳性对照组给予150 mg/kg帕妥珠单抗(Pertuzumab),辅料对照组给予空白溶剂(0 mg/kg)。各组动物按相应体重慢速静脉注射给药,给药体积为15 m L/kg,给药速度约5 m L/min。每周给药1次,共给药4周,恢复期4周,期间进行各项毒理学指标检测。结果:一般症状结果显示给药期间与给药后,低、中、高剂量组和阳性对照组陆续有动物出现腹泻症状。高剂量组1只动物在d40时濒死剖解,其最早出现稀便,停药后腹泻状态也未见好转,生化指标显示在d28时碱性磷酸酶(Alkaline Phosphatase,ALP)升高,在d14和d40时尿素(Blood Urea,BU)升高,总蛋白(Total Protein,TP)、白蛋白(Albumin,ALB)降低。低、高剂量组和阳性对照组均有部分动物白细胞(White Blood Cell,WBC)给药后数值降低,各给药组在d14时及高剂量组和阳性对照组在d28时BU升高或有升高的趋势,恢复期时有恢复趋势。高剂量濒死动物骨髓检查发现核红细胞较多,各阶段粒细胞减少,出现较多裸核;病理检查发现肾脏可见散在多发的中度肾小管扩张,近曲小管上皮轻度变性。其余指标包括一般症状、体重、尿液、心电图、免疫学指标等未见明显与供试品相关的异常变化。结论:SMMU-27主要毒性靶部位是胃肠道(腹泻)、肾脏(血清BU升高)和血液系统(WBC下降),应与这些部位表达供试品结合的相关受体有关,属供试品的药理作用放大和延伸。因此本实验条件下食蟹猴的安全剂量(NOAEL)为150 mg/kg,致死剂量为450 mg/kg。SMMU-27与等剂量阳性对照药物毒性反应基本类似。     

Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits

BACKGROUND : The present work was performed to determine the effect of thalidomide exposure on reproductive function and early embryonic development. METHODS : Twenty‐five female New Zealand White rabbits were orally gavaged with 0, 10, 50, or 100 mg/kg/day thalidomide 14 days prior to mating through to gestation day 7 for a total of 22 days. Treated females were Caesarean‐sectioned approximately 29 days after the date of attempted mating. Following mating with treated females, male rabbits (25/dose) were gavaged with 0, 30, 150, or 500 mg/kg/day beginning 14 days prior to mating with a group of untreated females (25/dose). Doses were administered through mating until the day before sacrifice for a minimum of 56 days. Untreated females were Caesarean‐sectioned 29 days after the last attempted mating. Comprehensive necropsy and histopathology of the reproductive system were performed. RESULTS : Treated females had reduction in body weight gain during gestation. Mating and pregnancy parameters were unaffected by thalidomide. At 100 m/kg, litter averages for corpora lutea, implantations, litter sizes, does with viable fetuses and live fetuses decreased and the number of early resorptions, does with any resorptions, does with all conceptuses resorbed, and the percent resorbed conceptuses per litter increased. The number of early resorptions, the average number of early resorptions per litter, and the percent resorbed conceptuses per litter increased at 10 and 50 mg/kg. There were no thalidomide‐related external fetal malformations. Mating and fertility in male rabbits were unaffected by thalidomide. There was an increased incidence of flaccid testes at 150 and 500 mg/kg and of bilateral small testes in all treated groups. At 500 mg/kg, there was degeneration of the germinal epithelium of the testicles with an increase in multinucleated giant cells in seminiferous tubule and a loss of round and elongating spermatids. CONCLUSIONS : Thalidomide had no adverse effects on mating and fertility in male and female rabbits dosed up to 500 and 100 mg/kg/day, respectively, for 14 days prior to mating. After 56 day of dosing, histopathologic changes with no associated sperm abnormalities were observed in the testicles. Embryonic development NOAEL for treated females mated to untreated males was <10 mg/kg. Corresponding fertility NOAEL for treated males mated to untreated females was 500 mg/kg. Birth Defects Res B 71:1–16, 2004. © 2004 Wiley‐Liss, Inc.     

Ultrastructural Changes in the Kidney of Rats with Acute Exposure to Cadmium and Effects of Exogenous Metallothionein

Ultrastructural changes in the kidneys of rats after acute cadmium exposure and the effects of exogenous metallothionein (MT) were studied by transmission electron microscopy. Thirty-six adult Wistar rats were divided into three groups. Cadmium chloride (CdCl₂) (3.5 mg/kg/day) was injected subcutaneously in the first group. In the second group, 30 μmol/kg MT was administered in addition to CdCl₂. Control rats received 0.5 ml subcutaneous saline solution. Four rats from each group were killed on days 1, 3, 5, and 7 after administration of the compounds. Kidney tissues were taken and fixed in 2.5% glutaraldehyde solution for electron microscopic observations. Tissue damage in kidney increased as time passed since the administration of CdCl₂ in the first group. Degeneration in the proximal and distal tubules was observed. Increased apoptosis was seen in the proximal tubules epithelium, especially on day 7. Peritubular capillaries became dilated, there was degeneration of the endothelial cells, and the amount of intertubular collagen fibers was increased. On day 1, irregular microvilli in the proximal tubules, deepening of the basal striations, and myelin figures; on day 3, multiple vesicular mitochondria and regions of edema around tubules; on days 5 and 7, increased apoptotic cell in the proximal tubules and widened rough endoplasmic reticulum of the endothelial cells of glomerular capillaries were observed. We observed that the structural alterations that increased depending on the day of Cd administration decreased after exogenous MT administration, the dilation of the peritubular capillaries persisted, and there were degenerated proximal tubules. It was established that cadmium chloride was toxic for kidney cortex and caused structural damage. Exogenous MT partly prevents CdCl₂-induced damage.     

Targeting Superoxide Dismutase to Renal Proximal Tubule Cells Attenuates Vancomycin-induced Nephrotoxicity in Rats

Vancomycin hydrochloride (VCM), a glycopeptide antibiotic, has a broad spectrum against methicillin-resistant Staphylococcus aureus (MRSA). As it is known to induce renal dysfunction, the dose and the duration of its administration are limited. Moreover, the mechanism of VCM-induced renal dysfunction remains to be unclear. To evaluate the involvement of free radical on VCM-induced renal dysfunction, we carried out analysis with a hexamethylenediamine-conjugated superoxide dismutase (AH-SOD) which rapidly accumulates in renal proximal tubule cells and inhibits oxidative injury of the kidney. Male Wistar rats (weighing 200-210 g) were intraperitonealy administered with 200 mg/kg of VCM twice a day for 7 days. AH-SOD 5 mg/kg/day was subcutaneously injected 5 min before every VCM injection. VCM induced renal injury dose-dependently. Biochemical analyses revealed that plasma levels of blood urea nitrogen and creatinine significantly increased in the VCM-treated group by an AH-SOD-inhibitable mechanism. VCM simultaneously elicited an increase of 8-OHdG levels and chemiluminescence intensity of free radical generation in the kidney. Histological examination revealed that VCM also elicited a marked destruction of glomeruli and necrosis of proximal tubules. AH-SOD inhibited these phenomena in the kidney. These results suggested that oxidative stress might underlie the pathogenesis of VCM-induced nephrotoxicity and targeting SOD and/or related antioxidants to renal proximal tubules might permit the administration of higher doses of VCM sufficient for eradication of MRSA without causing renal injury.     

Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats

Vancomycin hydrochloride (VCM), a glycopeptide antibiotic, has a broad spectrum against methicillin-resistant Staphylococcus aureus (MRSA). As it is known to induce renal dysfunction, the dose and the duration of its administration are limited. Moreover, the mechanism of VCM-induced renal dysfunction remains to be unclear. To evaluate the involvement of free radical on VCM-induced renal dysfunction, we carried out analysis with a hexamethylenediamine-conjugated superoxide dismutase (AH-SOD) which rapidly accumulates in renal proximal tubule cells and inhibits oxidative injury of the kidney. Male Wistar rats (weighing 200-210 g) were intraperitonealy administered with 200 mg/kg of VCM twice a day for 7 days. AH-SOD 5 mg/kg/day was subcutaneously injected 5 min before every VCM injection. VCM induced renal injury dose-dependently. Biochemical analyses revealed that plasma levels of blood urea nitrogen and creatinine significantly increased in the VCM-treated group by an AH-SOD-inhibitable mechanism. VCM simultaneously elicited an increase of 8-OHdG levels and chemiluminescence intensity of free radical generation in the kidney. Histological examination revealed that VCM also elicited a marked destruction of glomeruli and necrosis of proximal tubules. AH-SOD inhibited these phenomena in the kidney. These results suggested that oxidative stress might underlie the pathogenesis of VCM-induced nephrotoxicity and targeting SOD and/or related antioxidants to renal proximal tubules might permit the administration of higher doses of VCM sufficient for eradication of MRSA without causing renal injury.     

Developmental toxicity evaluation of sodium thioglycolate administered topically to Sprague-Dawley (CD) rats and New Zealand White rabbits

BACKGROUND: Sodium thioglycolate, which has widespread occupational and consumer exposure to women from cosmetics and hair‐care products, was evaluated for developmental toxicity by topical exposure during the embryonic and fetal periods of pregnancy METHODS: Timed‐mated Sprague–Dawley rats (25/group) and New Zealand White (NZW) rabbits (24/group) were exposed to sodium thioglycolate in vehicle (95% ethanol:distilled water, 1:1) by unoccluded topical application on gestational days (GD) 6–19 (rats) or 6–29 (rabbits) for 6 hr/day, at 0, 50, 100, or 200 mg/kg body weight/day (rats) and 0, 10, 15, 25, or 65 mg/kg/day (rabbits). At termination (GD 20 rats; GD 30 rabbits), fetuses were examined for external, visceral, and skeletal malformations and variations. RESULTS: In rats, maternal topical exposure to sodium thioglycolate, at 200 mg/kg/day (the highest dose tested) on GD 6–19, resulted in maternal toxicity, including reduced body weights and weight gain, increased relative water consumption and one death. Treatment‐related increases in feed consumption and changes at the application site occurred at all doses, in the absence of increased body weights or body weight change. Fetal body weights/litter were decreased at 200 mg/kg/day, with no other embryo/fetal toxicity and no treatment‐related teratogenicity in any group. In rabbits, maternal topical exposure to sodium thioglycolate on GD 6–29 resulted in maternal dose‐related toxicity at the dosing site in all groups; no maternal systemic toxicity, embryo/fetal toxicity, or treatment‐related teratogenicity were observed in any group. CONCLUSIONS: A no observed adverse effect level (NOAEL) was not identified for maternal toxicity in either species with the dosages tested. The developmental toxicity NOAEL was 100 mg/kg/day (rats) and ≥65 mg/kg/day (rabbits; the highest dose tested). The clinical relevance of theses study results is uncertain because no data were available for levels, frequency, or duration of exposures in female workers or end users. Birth Defects Research Part B 68:144–161, 2003. © 2003 Wiley‐Liss, Inc.     

Inverse relationship between renal and urinary kallikrein during chromate-induced acute renal failure in rat: urinary kallikrein excretion as a possible recovery index

Acute renal failure (ARF) was induced in rat following a single injection of sodium chromate. A transient polyuria and a 10-fold decrease in glomerular filtration rate was immediately observed after sodium chromate administration. Urinary sodium and potassium excretion were reduced within 24 h and remained decreased for 8 to 10 days. Progressive recovery of normal renal functions, mainly electrolyte excretion and filtration rate was observed 12 days after sodium chromate administration. Urinary kallikrein excretion (UKE) was decreased only 48 h after sodium chromate administration. However the proportion of the active and inactive form excreted was unchanged. UKE remained also at a reduced level for 8 to 10 days and returned progressively to base-line level. The kallikrein content in the tissue was significantly increased immediately after sodium chromate administration and recovered normal values 12 days later. The increase of kallikrein in the tissue is more likely unspecific due to impaired protein transport than a specific stimulation of renal kallikrein biosynthesis. The decreased UKE may indicate a distal tubular reversible dysfunction in this ARF model. These reductions in electrolyte excretion, glomerular filtration and UKE were associated with selective morphological lesions. Whereas the glomeruli were intact, important damages affected proximal tubule cells which appeared necrotic and showed presence of vacuoles, liquefaction of cytoplasmic material and lost of microvilli. Less marked lesions were however observed in distal tubules, particularly large vacuoles were present at the apical poles of the tubule cells, the sites of kallikrein secretion. These distal damages may be involved in the increase of tissue concentration and in the decrease of UKE.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of selected indicators of the renal proximal tubule function in patients treated with gentamicin]

The study aimed at evaluating proximal renal tubule function in patients with nephrolithiasis and chronic pyelonephritis, and in patients with infectious diseases treated with gentamicin. The study involved 2 groups of patients: group A--17 patients with nephrolithiasis and chronic pyelonephritis and group B--30 patients with other infectious diseases (pneumonia, biliary tract infections) but with normal glomerular filtration rate. Patients from both groups were treated with gentamicin in a daily dose of 2-3 mg/kg for 7-10 days. Serum and urine creatinine levels were assayed in all patients prior to, 2-3, 7, 10 days, and after the treatment. Patients assigned to group B were divided into two subgroups: B1 included 15 patients with normal beta 2-microglobulinuria, and B2 15 patients with increased renal loss of beta 2-microglobulin and decreased tubular reabsorption of this protein. Significant increase in beta 2-microglobulinuria was seen on the third day of therapy, the decrease in the tubular reabsorption and glomerular filtration rate were noted in all patients on the seventh day of gentamicin administration. Beta 2-microglobulinuria was significantly higher in patients from groups A and B2 in comparison with group B1 in which no dysfunction of the proximal renal tubule was present before gentamicin therapy. A degree of beta 2-microglobulinuria is an early and sensitive indicator of gentamicin nephrotoxicity. The risk of nephrotixic symptoms is particularly obvious in patients with deteriorated function of renal proximal tubuli before the treatment with gentamicin.